Adenoviral Vector for Enhanced Prostate Cancer Specific Transferrin Conjugated Drug Targeted Therapy.

Abstract

Prostate cancer (PCa) is one of the leading causes of death for men worldwide. Unlike some other types of cancer, there is a lack of targeted therapy for prostate cancer patients that can kill cancer cells but do much less damage to the normal tissue. In this paper, we report on an adenoviral vector enhanced prostate cancer specific transferrin conjugated drug targeted therapy. In particular, a functional PCa-specific gene probe is introduced to drive and up-regulate the transferrin receptor expression on the PCa via adenoviral vector. As a result, significantly enhanced accumulation of nanoscale transferrin-doxorubicin (Tf-DOX) protein drug conjugates and concomitant notably elevated PCa tumor inhibition are observed. This conceptual strategy provides the proof-of-concept for the targeted therapy of PCa that is highly desired but not yet developed.

• Authors: Jing Peng, Kangkang Liu, Lin Cao, Dengyi Duan, Guodong Song, Shuang Liu, Lining Wang, Jianmin Li, Xuening Zhang, Kai Huang, Yang Zhao, Yuanjie Niu, Gang Han
• Journal: Nano letters (Nano Lett) Vol. 22 Issue 10 Pg. 4168-4175 (05 25 2022) ISSN: 1530-6992 [Electronic] United States
• PMID: 35522032 (Publication Type: Journal Article)

Chemical References

• Transferrin
• Doxorubicin

Topics

• Adenoviridae (genetics)
• Cell Line, Tumor
• Doxorubicin (pharmacology, therapeutic use)
• Drug Delivery Systems
• Genetic Vectors
• Humans
• Male
• Prostatic Neoplasms (drug therapy, genetics)
• Transferrin (therapeutic use)